ONCO (Onconetix) ROIC %: -44.35% (As of Mar. 2026)


ONCO Onconetix Inc ONCO
23 GF Score
Price $1.14
! 4 Warning Signs
View Full Analysis

What is Onconetix ROIC %?

Onconetix ONCO +20.37% 23 ROIC % is -44.35% as of Mar. 2026. GuruFocus rates ONCO with a GF Score™ of 23/100. The stock has 4 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Onconetix's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was -44.35%.

As of today (2026-06-30), Onconetix's WACC % is 15.11%. Onconetix's ROIC % is -27.59% (calculated using TTM income statement data). Onconetix earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Onconetix  (NAS:ONCO) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Onconetix's WACC % is 15.11%. Onconetix's ROIC % is -27.59% (calculated using TTM income statement data). Onconetix earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Onconetix ROIC % Related Terms


Onconetix ROIC % Historical Data

* Premium members only.

The historical data trend for Onconetix's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onconetix ROIC % Chart

Onconetix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial -1,005.00 -1,867.17 -38.34 -15.76 -20.19

Onconetix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.12 -20.34 -27.82 -17.55 -44.35

ONCO vs CMND, REVB, PPCB: ROIC % Comparison

For the Biotechnology subindustry, Onconetix's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Onconetix ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Onconetix's ROIC % distribution charts can be found below:

* The bar in red indicates where Onconetix's ROIC % falls into.


ONCO
23GF Score
Onconetix Inc ONCO
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Onconetix ROIC % Calculation

Onconetix's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-6.345 * ( 1 - 0% )/( (36.909 + 25.939)/ 2 )
=-6.345/31.424
=-20.19 %

where

Onconetix's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2026 is calculated as:

ROIC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-8.368 * ( 1 - 0% )/( (25.939 + 11.799)/ 2 )
=-8.368/18.869
=-44.35 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -44.35% mean?
Onconetix (ONCO) has a ROIC % of -44.35% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Onconetix and its competitors.
Is Onconetix's ROIC % too high?
Onconetix's current ROIC % is -44.35%. Overall, Onconetix has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Onconetix's ROIC % compare to CMND and REVB?
Onconetix's ROIC % of -44.35% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on Onconetix and its competitors. Onconetix's current ROIC % is -44.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onconetix stock overvalued right now?
Onconetix (ONCO) has a current ROIC % of -44.35%. The current ROIC % is -44.35%. Onconetix's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For Onconetix (ONCO), the current ROIC % is -44.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Onconetix Business Description

Address 201 E. Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
23GF Score

Get the complete analysis for ONCO

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.14
Price